17.05.2019 • NewsCristalElaine BurridgeVenator

Venator Sues Tronox over Cristal Contract

Venator Sues Tronox over Cristal Contract (c) StudioSmart/Shutterstock
Venator Sues Tronox over Cristal Contract (c) StudioSmart/Shutterstock

Venator Materials has started a lawsuit against Tronox in the Delaware Superior Court. The lawsuit, said Venator, is because Tronox has refused to honor a contract to pay a $75 million break fee over the sale of Cristal’s North American titanium dioxide (TiO2) business.

Tronox was required to sell the business to resolve US Federal Trade Commission (FTC) competition concerns over its merger with Cristal. An attempt to sell the assets in Ashtabula, Ohio, to Venator failed, and Tronox eventually sold the business to Ineos.

"It is unfortunate that Tronox has failed to honor its contract with Venator and offers baseless excuses for its refusal to perform. Venator at all times acted in good faith during its negotiations with Tronox,” said the company’s president and CEO, Simon Turner.

For example, Turner said, with Tronox's consent, Venator met with the FTC to make a presentation on its proposed acquisition of Ashtabula. While Venator was preparing to further respond to the issues raised by the FTC, Tronox abruptly terminated the bilateral discussions to pursue an alternative transaction. Having sold the business to a buyer other than Venator, Tronox must now pay the break fee.

Jeffry Quinn, chairman and CEO of Tronox, took a different view. Due to Venator’s failure to adhere to the terms of the Memorandum of Understanding (MoU), he said Tronox ultimately was forced to sell Cristal’s North American operations for $700 million, substantially less than was contemplated by the MoU.

“We believe that Venator’s failure to negotiate in good faith to purchase Cristal’s North American operations for $1.1 billion, as contemplated by the MoU, and its failure to otherwise comply with the MOU obviates Tronox’s need to pay the break fee,” Quinn said.

In the lawsuit, Venator is seeking a judgement for $75 million plus pre- and post-judgement interest and its “reasonable” attorneys’ fees and costs.

 

Interview

Stability in Motion
Strategic Response to a Shifting Pharma Landscape

Stability in Motion

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.

Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

most read